1. Home
  2. CINT vs PHAR Comparison

CINT vs PHAR Comparison

Compare CINT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINT
  • PHAR
  • Stock Information
  • Founded
  • CINT 1995
  • PHAR 1988
  • Country
  • CINT Brazil
  • PHAR Netherlands
  • Employees
  • CINT N/A
  • PHAR N/A
  • Industry
  • CINT EDP Services
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CINT Technology
  • PHAR Health Care
  • Exchange
  • CINT Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • CINT 803.4M
  • PHAR 731.1M
  • IPO Year
  • CINT 2021
  • PHAR N/A
  • Fundamental
  • Price
  • CINT $5.96
  • PHAR $10.39
  • Analyst Decision
  • CINT Buy
  • PHAR Strong Buy
  • Analyst Count
  • CINT 7
  • PHAR 3
  • Target Price
  • CINT $7.61
  • PHAR $30.00
  • AVG Volume (30 Days)
  • CINT 101.9K
  • PHAR 3.7K
  • Earning Date
  • CINT 08-15-2025
  • PHAR 07-31-2025
  • Dividend Yield
  • CINT N/A
  • PHAR N/A
  • EPS Growth
  • CINT 53.80
  • PHAR N/A
  • EPS
  • CINT 0.24
  • PHAR N/A
  • Revenue
  • CINT $444,135,000.00
  • PHAR $320,708,000.00
  • Revenue This Year
  • CINT $526.02
  • PHAR $13.31
  • Revenue Next Year
  • CINT $12.77
  • PHAR $7.68
  • P/E Ratio
  • CINT $24.89
  • PHAR N/A
  • Revenue Growth
  • CINT 3.04
  • PHAR 24.13
  • 52 Week Low
  • CINT $4.42
  • PHAR $6.65
  • 52 Week High
  • CINT $8.04
  • PHAR $12.61
  • Technical
  • Relative Strength Index (RSI)
  • CINT 52.04
  • PHAR 47.23
  • Support Level
  • CINT $5.89
  • PHAR $9.88
  • Resistance Level
  • CINT $5.94
  • PHAR $10.59
  • Average True Range (ATR)
  • CINT 0.18
  • PHAR 0.31
  • MACD
  • CINT 0.02
  • PHAR -0.12
  • Stochastic Oscillator
  • CINT 72.73
  • PHAR 31.68

About CINT CI&T Inc

CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: